Revised Law Includes Designated Funding for Rare Diseases
Cystic Fibrosis Foundation Drug Development Model Spawns More Than 30 Promising Therapies
Today, the Cystic Fibrosis Foundation announced a new award of up to $2 million to Eloxx Pharmaceuticals Inc. to support the global Phase 2 clinical program of ELX-02, a potential therapy to treat people with cystic fibrosis who have nonsense mutations.
Today, the Cystic Fibrosis Foundation announced that it has awarded up to $400,000 to Life Edit Therapeutics Inc. to explore the application of their unique gene editing technology in CF.
Funding will support improved detection, diagnosis, prevention, and treatment of infections related to cystic fibrosis.
New funding will support clinical development of two novel therapies to address complications of cystic fibrosis